130018-87-0

130018-87-0 structure

Name: Levocetirizine dihydrochloride
Chemical Name: Levocetirizine Dihydrochloride
CAS Number: 130018-87-0
Molecular Formula: C₂₁H₂₇Cl₃N₂O₃
Molecular Weight: 461.810
Catalog: API Antiallergic Antihistamine
Create Date: 2018-06-26 13:48:04
Modify Date: 2024-01-02 15:31:02
Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].

Name	Levocetirizine Dihydrochloride
Synonyms	Xyzall EINECS 200-659-6 (R)-Cetirizine Dihydrochloride Levocetirizine dihydrochloride (2-{4-[(R)-(4-Chlorphenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)essigsäuredihydrochlorid MFCD07366507 (-)-Cetirizine dihydrochloride Levocetirizine 2HCl Xusal (2-{4-[(R)-(4-Chlorophenyl)(phenyl)methyl]-1-piperazinyl}ethoxy)acetic acid dihydrochloride 2-[2-[4-[(R)-(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic Acid Dihydrochloride Xyzal acide (2-{4-[(R)-(4-chlorophényl)(phényl)méthyl]pipérazin-1-yl}éthoxy)acétique dichlorhydrate acetic acid, [2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, dihydrochloride Acetic acid, 2-[2-[4-[(R)-(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-, hydrochloride (1:2) (2-{4-[(R)-(4-Chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid dihydrochloride

Description	Levocetirizine dihydrochloride ((R)-Cetirizine dihydrochloride) is a third-generation peripheral H1-receptor antagonist. Levocetirizine dihydrochloride is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine dihydrochloride has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Endocrinology Research Areas >> Inflammation/Immunology Signaling Pathways >> GPCR/G Protein >> Histamine Receptor
In Vivo	Levocetirizine (0.4 mg/kg; oral administration; male Sprague-Dawley rats) treatment shows that the Cmax, AUC0-t , AUC0-∞ and t1/2 are 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively in Sprague-Dawley rats[1]. Animal Model: 30 male Sprague-Dawley rats (8 weeks old; 200-250 g)[1] Dosage: 0.4 mg/kg Administration: Oral administration (Pharmacokinetic Analysis) Result: The Cmax, AUC0-t , AUC0-∞ and t1/2 were 0.34 μg/mL, 3.26 μg h/mL, 3.67 μg h/mL and 2.34 hours, respectively.
References	[1]. Lohar P, et al. Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley rats. Biomed Chromatogr. 2019 Dec;33(12):e4672.

HS Code	2933599090
Summary	2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%